

New Data on AC Immune's Abeta and pTau Clinical Programs in Alzheimer's Disease To Be Presented at CTAD 2021

Lausanne, Switzerland, November 2, 2021 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announces that new data on its investigational Alzheimer's disease (AD) candidates semorinemab, ACI-35.030 and ACI-24 will be featured in the scientific program of the *Clinical Trials on Alzheimer's Disease* (C-TAD) Conference, taking place virtually and in person in Boston, on November 9-12, 2021.

Scientific updates at CTAD 2021

Semorinemab monoclonal anti-tau antibody

Title: *Phase 2 Trial of Semorinemab in Mild-to-Moderate Alzheimer's Disease (Lauriet): Topline results*

Presenter: late-breaking readout roundtable by Cecilia Monteiro

Date: Wednesday November, 10 | 10.50am-11.20am EST | In-person session streamed live in the digital platform of CTAD | Available on demand 48 hours after the session

ACI-35.030 Anti-pTau Vaccine

Title: *ACI-35.030, a novel anti-phospho-Tau vaccine for the treatment of Alzheimer's Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity*

Presenter: oral presentation by Johannes Streffer

Date: Friday, November 12 | Available on demand in the digital platform of CTAD from 08:00am EST

ACI-24 anti-beta amyloid vaccine

Title: *ACI-24, an anti-beta amyloid vaccine, in patients with mild Alzheimer's disease: Results of a phase 2, randomized, double-blind, placebo-controlled study*

Presenter: Poster P44 presented by Olivier Sol

Date: November 9-12 | Available on the digital platform of CTAD at all times

About AC Immune SA

AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track

record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >\$3 billion in potential milestone payments.

SupraAntigen[®] is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU. Morphomer[®] is a registered trademark of AC Immune SA in CN, CH, GB, JP, and NO.

For further information, please contact:

Media Relations

Saoyuth Nidh
AC Immune
Phone: +41 21 345 91 34
Email: saoyuth.nidh@acimmune.com

Investor Relations

Yves Kremer, Ph.D.
AC Immune
Phone: +41 21 345 91 90
Email: yves.kremer@acimmune.com

U.S. Media

Shani Lewis
LaVoieHealthScience
Phone: +1 609 516 5761
Email: slewis@lavoiehealthscience.com

U.S. Investors

Corey Davis, Ph.D.
LifeSci Advisors
Phone: +1 212 915 2577
Email: cdavis@lifesciadvisors.com

Forward looking statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.